

# Cutaneous Melanoma in a Dachshund

**Heather M. Wilson-Robles, DVM, DACVIM (Oncology)**  
*Texas A&M University*



Buster, a 7-year-old neutered male dachshund, was presented for evaluation of a pigmented, nonhaired growth <1 cm in diameter of a month's duration near his left eye. Although the mass was not painful, it was superficially ulcerated and Buster scratched at it often. The mass was incompletely excised from near the left medial canthus and submitted for histopathologic evaluation. Excision was incomplete to avoid disrupting the eyelid margin.

Buster was diagnosed with cutaneous melanoma based on histopathologic evaluation of the excised mass, which was determined to be malignant based on its mitotic index (MI) of 10, as cutaneous melanoma with an MI >3 is considered to be malignant.<sup>1-3</sup> According to the biopsy report, the tumor tissue was composed of sheets of pigmented and

nonpigmented atypical mesenchymal cells arranged in storiform patterns in the dermis. Nuclei were round-to-oval, with few distinct prominent nucleoli. Many tumor cells contained melanin granules. Radiation therapy (RT) for the incompletely excised melanoma was initially recommended; however, because of concern for damage to the eyes from external beam radiation due to the close proximity of the tumor to the eye, Buster was referred to a local university hospital for strontium 90 RT.

Adjunctive plesiotherapy with strontium 90 uses  $\beta$ -particle emissions to deliver radiation directly to the skin. Unlike gamma-particle RT, which is used with external beam RT,  $\beta$ -particle RT provides the required surface dose of radiation but has a rapid decrease of the dose beneath the surface of the skin, as  $\beta$  particles only penetrate a few millimeters into the skin, making  $\beta$ -particle RT appropriate only in cases of very superficial inflammatory or neoplastic lesions. Only minimal shielding is required with  $\beta$ -particle RT due to the inability of  $\beta$  particles to penetrate even thin layers of

MI = mitotic index

RT = radiation therapy

steel; this allows for precise treatment with high doses of radiation to small and superficial lesions.

### Physical Examination

On presentation for strontium 90 RT, Buster was bright, alert, and responsive. No significant abnormalities were identified, with the exception of moderate dental tartar and a small scar on the medial canthus of the left eye where the primary tumor had been removed.

### Diagnosis & Staging

There was no obvious mass at the site of the primary tumor. Regional lymph nodes were palpated and were normal. Lung sounds were also normal. Staging was performed and included aspiration of the regional submandibular lymph nodes and 3-view thoracic radiography, which was normal. Buster was determined to have stage I cutaneous melanoma. Advanced imaging (ie, CT) to include the retropharyngeal and periorbital lymph nodes was declined by the owner. Minimum database (ie, CBC, serum chemistry profile, urinalysis) was also normal.

Although melanoma was easily diagnosed via histopathology in Buster's case, histopathology may not be enough to confirm a diagnosis of melanoma. In such cases, immunohistochemical stains may be necessary to make a definitive diagnosis.<sup>1</sup>

### Treatment & Long-Term Management

Buster was premedicated for strontium 90 treatment with butorphanol (0.2 mg/kg IM), induced with propofol to effect, and intubated. Anesthesia was maintained using 1.5% to 2% isoflurane inhalant. A 1.8-cm strontium 90 probe was placed over the scarred area and maintained for 6 minutes and 53 seconds to deliver a total dose of 100 Gy to the surface of the skin.

At the recheck examination 2 weeks after RT, a white scab over the treated area, mild blanching of the skin, and mild moist desquamation were observed, all of which resolved after an additional week of supportive care.

Adjuvant therapy, including carboplatin chemotherapy and the melanoma vaccine, was recommended to address potential metastatic disease but was declined. Continued monitoring for evidence of local recurrence and metastatic disease with physical examinations, regional lymph node evaluations, and thoracic radiography for the next 3 years was also suggested but declined (see *Treatment at a Glance*).

Continues ►

**Patients with incompletely excised, malignant cutaneous tumors should be treated with additional surgery or local radiation therapy.**

### TREATMENT AT A GLANCE

- Complete surgical excision is the mainstay of treatment and is curative in approximately 80% of patients with cutaneous melanoma.<sup>7,9</sup>
- Patients with incompletely excised, malignant cutaneous tumors should be treated with additional surgery or local RT.
- Malignant tumors not amenable to surgical excision may be treated with local RT alone (typically 6 fractions of 6 Gy each).<sup>10</sup>
- Adjuvant therapy should be considered for malignant melanomas of the skin. Adjuvant therapy can include radiation of locoregional lymph node beds and sentinel lymph nodes,<sup>10</sup> carboplatin chemotherapy,<sup>11</sup> and immunotherapy (ie, melanoma vaccine).<sup>12</sup>
- Monitoring programs should be implemented after therapy for patients with tumors deemed malignant. Monitoring should include physical examination, thoracic radiography, regional lymph node evaluation, and evaluation of any new masses.

## TAKE-HOME MESSAGES

- ▶ Cutaneous melanoma comprises 4% of all skin tumors in dogs, of which 80% to 90% are benign and 10% to 20% are malignant.<sup>7,9</sup>
- ▶ The following histologic features have been associated with a more aggressive clinical course<sup>1</sup>:
  - MI >3
  - More than 20% of cells displaying nuclear atypia
  - Low degree of cell pigmentation
  - Expansion beyond the dermis
  - Ulceration of the overlying epithelium
  - Ki67 expression in >15% of cells
- ▶ Histopathology and, possibly, a melanoma prognostic panel (see **Suggested Reading**) should be used to determine the prognosis of the mass.
- ▶ Up to 40% of lymph nodes in patients with metastatic melanoma are normal in size, so lymph node aspiration should be conducted for proper staging.<sup>13</sup>
- ▶ The metastatic rate for malignant melanoma has been reported to be 40% to 60%, regardless of primary location.<sup>3,7,8,14</sup>
- ▶ At minimum, proper staging should include baseline minimum database (eg, CBC, serum chemistry profile, urinalysis), regional lymph node aspiration, and 3-view thoracic radiography. Advanced imaging (eg, CT, MRI) may be warranted for some mass locations (eg, oral cavity, pharynx, rectum, anal sac, other internal organs not immediately accessible to physical examination). In addition, CT-guided sentinel lymph node mapping has been proven to be beneficial in humans and may therefore be prognostically useful for staging in dogs.<sup>15</sup>

## RELATED ARTICLE

See accompanying article, **Management of Cutaneous Melanoma**, on page 32.

MI = mitotic index

## Prognosis & Outcome

Most cases of cutaneous melanoma diagnosed on haired skin are benign; however, cutaneous melanoma associated with a mucocutaneous junction, a nail bed, or the oral cavity is often malignant and has aggressive clinical behavior. Melanomas arising from haired skin can occasionally be malignant with an aggressive clinical course (≈12% of melanomas from haired skin)<sup>4</sup>; thus, all pigmented or partially pigmented skin masses that are removed should be submitted for histopathologic evaluation to determine the surgical margins, MI, and any additional features of malignancy.

Dogs with benign cutaneous melanoma are typically younger (median age, 8.1 years) than those with malignant melanoma (median age, 11.6 years) at diagnosis.<sup>4</sup> A better prognosis for cutaneous melanoma is generally associated with an MI <3, <20% of cells displaying nuclear atypia, a higher degree of pigmentation (>50% of cells), containment within the dermis, no ulceration of overlying skin, and a Ki67 score of <15% (out of 500 counted cells).<sup>5</sup> The median 2-year survival rate in dogs with cutaneous melanoma is 84%, unless the tumor is associated with a digit (median 2-year survival rate, 56%).<sup>2</sup> In another study, ulceration of cutaneous masses was associated with a significantly shorter survival rate, although a separate study did not find ulceration to be a prognostic factor.<sup>2,3,6</sup>

The prognosis for stage I cutaneous melanoma can be quite good if the MI is <3 but guarded if the MI is higher. The metastatic rate for malignant mucosal melanoma, which spreads most commonly to the lungs and regional lymph nodes, is approximately 60% (see **Take-Home Messages**).<sup>3,7,8</sup>

An update provided by the owner indicated that Buster was doing well 56 months postdiagnosis, with no evidence of metastasis or spread of the original tumor, despite the high MI. No additional therapy was performed during this 56-month period. ■

## References

1. Smedley RC, Lamoureux J, Sledge DG, Kiupel M. Immunohistochemical diagnosis of canine oral amelanotic melanocytic neoplasms. *Vet Pathol*. 2011;48(1):32-40.
2. Laprie C, Abadie J, Amardeilh MF, Net JL, Lagadic M, Delverdiere M. MIB-1 immunoreactivity correlates with biologic behaviour in canine cutaneous melanoma. *Vet Dermatol*. 2001;12(3):139-147.
3. Bostock DE. Prognosis after surgical excision of canine melanomas. *Vet Pathol*. 1979;16(1):32-40.
4. Bolon B, Calderwood Mays MB, Hall BJ. Characteristics of canine melanomas and comparison of histology and DNA ploidy to their biologic behavior. *Vet Pathol*. 1990;27(2):96-102.
5. Smedley RC, Spangler WL, Esplin DG, et al. Prognostic markers for canine melanocytic neoplasms: a comparative review of the literature and goals for future investigation. *Vet Pathol*. 2011;48(1):54-72.
6. Schultheiss PC. Histologic features and clinical outcomes of melanomas of lip, haired skin, and nail bed locations of dogs. *J Vet Diagn Invest*. 2006;18(4):422-425.
7. Spangler WL, Kass PH. The histologic and epidemiologic bases for prognostic considerations in canine melanocytic neoplasia. *Vet Pathol*. 2006;43(2):136-149.
8. Bergman PJ. Canine oral melanoma. *Clin Tech Small Anim Pract*. 2007;22(2):55-60.
9. Goldschmidt MH. Pigmented lesions of the skin. *Clin Dermatol*. 1994;12(4):507-514.
10. Freeman KP, Hahn KA, Harris FD, King GK. Treatment of dogs with oral melanoma by hypofractionated radiation therapy and platinum-based chemotherapy (1987-1997). *J Vet Intern Med*. 2003;17(1):96-101.
11. Dank G, Rassnick KM, Sokolovsky Y, et al. Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision. *Vet Comp Oncol*. 2014;12(1):78-84.
12. Grosenbaugh DA, Leard AT, Bergman PJ, et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. *Am J Vet Res*. 2011;72(12):1631-1638.
13. Williams LE, Packer RA. Association between lymph node size and metastasis in dogs with oral malignant melanoma: 100 cases (1987-2001). *J Am Vet Med Assoc*. 2003;222(9):1234-1236.
14. Henry CJ, Brewer WG Jr, Whitley EM, et al. Canine digital tumors: a veterinary cooperative oncology group retrospective study of 64 dogs. *J Vet Intern Med*. 2005;19(5):720-724.
15. Leong SP, Accorrt NA, Essner R, et al. Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients. *Arch Otolaryngol Head Neck Surg*. 2006;132(4):370-373.

## Suggested Reading

Michigan State University Veterinary Diagnostic Laboratory. Diagnosis and prognosis of canine melanocytic tumors. MSU Veterinary Diagnostic Laboratory website. <https://www.animalhealth.msu.edu/ClientEducation/MKTG.CARD.ANATOMICPATHOLOGY.004.PDF>. Accessed May 28, 2019.

**The prognosis for stage I cutaneous melanoma can be quite good if the mitotic index is <3 but guarded if the mitotic index is higher.**

## Advantage Multi® for Dogs and for Cats (imidacloprid + moxidectin)

**BRIEF SUMMARY:** Before using Advantage Multi® for Dogs (imidacloprid+moxidectin) or Advantage Multi® for Cats (imidacloprid +moxidectin), please consult the product insert, a summary of which follows:

**CAUTION:** Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian. **Advantage Multi for Dogs:**

### WARNING

- DO NOT ADMINISTER THIS PRODUCT ORALLY.
  - For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals.
  - Children should not come in contact with the application sites for two (2) hours after application.
- (See Contraindications, Warnings, Human Warnings, and Adverse Reactions for more information.)

### INDICATIONS:

**Advantage Multi for Dogs** is indicated for the prevention of heartworm disease caused by *Dirofilaria immitis* and the treatment of *Dirofilaria immitis* circulating microfilariae in heartworm-positive dogs. **Advantage Multi for Dogs** kills adult fleas and is indicated for the treatment of flea infestations (*Ctenocephalides felis*). **Advantage Multi for Dogs** is also indicated for the treatment and control of sarcoptic mange caused by *Sarcoptes scabiei var. canis*. **Advantage Multi for Dogs** is also indicated for the treatment and control of the following intestinal parasites species: Hookworms (*Ancylostoma caninum*) (*Uncinaria stenocephala*), Roundworms (*Toxocara canis*) (*Toxascaris leonina*) and Whipworms (*Trichuris vulpis*).

**Advantage Multi for Cats** is indicated for the prevention of heartworm disease caused by *Dirofilaria immitis*. **Advantage Multi for Cats** kills adult fleas (*Ctenocephalides felis*) and is indicated for the treatment of flea infestations. **Advantage Multi for Cats** is also indicated for the treatment and control of ear mite (*Otodectes cynotis*) infestations and the intestinal parasites species Hookworm (*Ancylostoma tubaeforme*) and Roundworm (*Toxocara cati*). **Ferrets:** **Advantage Multi for Cats** is indicated for the prevention of heartworm disease in ferrets caused by *Dirofilaria immitis*. **Advantage Multi for Cats** kills adult fleas (*Ctenocephalides felis*) and is indicated for the treatment of flea infestations in ferrets.

**CONTRAINDICATIONS:** Do not administer this product orally. (See WARNINGS). Do not use the Dog product (containing 2.5% moxidectin) on Cats.

### WARNINGS:

**Advantage Multi for Dogs:** For the first 30 minutes after application: Ensure that dogs cannot lick the product from application sites on themselves or other treated dogs, and separate treated dogs from one another and from other pets to reduce the risk of accidental ingestion. Ingestion of this product by dogs may cause serious adverse reactions including depression, salivation, dilated pupils, incoordination, panting, and generalized muscle tremors. In avermectin sensitive dogs, the signs may be more severe and may include coma and death.<sup>a</sup>

<sup>a</sup> Some dogs are more sensitive to avermectins due to a mutation in the MDR1 gene. Dogs with this mutation may develop signs of severe avermectin toxicity if they ingest this product. The most common breeds associated with this mutation include Collies and Collie crosses.

<sup>b</sup> Although there is no specific antagonist for avermectin toxicity, even severely affected dogs have completely recovered from avermectin toxicity with intensive veterinary supportive care.

**Advantage Multi for Cats:** Do not use on sick, debilitated, or underweight cats. Do not use on cats less than 9 weeks of age or less than 2 lbs. body weight. Do not use on sick or debilitated ferrets.

**HUMAN WARNINGS:** Not for human use. Keep out of the reach of children. Dogs: Children should not come in contact with the application sites for two (2) hours after application. Cats: Children should not come in contact with the application site for 30 minutes after application.

Causes eye irritation. Harmful if swallowed. Do not get in eyes or on clothing. Avoid contact with skin. Wash hands thoroughly with soap and warm water after handling. If contact with eyes occurs, hold eyelids open and flush with copious amounts of water for 15 minutes. If eye irritation develops or persists, contact a physician. If swallowed, call poison control center or physician immediately for treatment advice. Have person sip a glass of water if able to swallow. Do not induce vomiting unless told to do so by the poison control center or physician. People with known hypersensitivity to benzyl alcohol, imidacloprid, or moxidectin should administer the product with caution. In case of allergic reaction, contact a physician. If contact with skin or clothing occurs, take off contaminated clothing. Wash skin immediately with plenty of soap and water. Call a poison control center or physician for treatment advice. The Safety Data Sheet (SDS) provides additional occupational safety information. For a copy of the Safety Data Sheet (SDS) or to report adverse reactions call Bayer Veterinary Services at 1-800-422-9874. For consumer questions call 1-800-255-6826.

**PRECAUTIONS:** Do not dispense dose applicator tubes without complete safety and administration information. Use with caution in sick, debilitated or underweight animals. The safety of **Advantage Multi for Dogs** has not been established in breeding, pregnant, or lactating dogs. The safe use of **Advantage Multi for Dogs** has not been established in puppies and dogs less than 7 weeks of age or less than 3 lbs. body weight. **Advantage Multi for Dogs** has not been evaluated in heartworm-positive dogs with Class 4 heartworm disease.

Cats may experience hypersalivation, tremors, vomiting and decreased appetite if **Advantage Multi for Cats** is inadvertently administered orally or through grooming/licking of the application site. The safety of **Advantage Multi for Cats** has not been established in breeding, pregnant, or lactating cats. The effectiveness of **Advantage Multi for Cats** against heartworm infections (*D. immitis*) after bathing has not been evaluated in cats. Use of this product in geriatric cats with subclinical conditions has not been adequately studied. Ferrets: The safety of **Advantage Multi for Cats** has not been established in breeding, pregnant, or lactating ferrets. Treatment of ferrets weighing less than 2.0 lbs. (0.9kg) should be based on a risk-benefit assessment. The effectiveness of **Advantage Multi for Cats** in ferrets weighing over 4.4 lbs. (2.0 kg) has not been established.

**ADVERSE REACTIONS: Heartworm Negative Dogs:** The most common adverse reactions observed during field studies were pruritus, residue, medicinal odor, lethargy, inappetence and hyperactivity. **Heartworm Positive Dogs:** The most common adverse reactions observed during field studies were cough, lethargy, vomiting, diarrhea (including hemorrhagic), and inappetence. **Cats:** The most common adverse reactions observed during field studies were lethargy, behavioral changes, discomfort, hypersalivation, polydipsia and coughing and gagging. **Ferrets:** The most common adverse reactions observed during field studies were pruritus/scratching, scabbing, redness, wounds and inflammation at the treatment site; lethargy; and chemical odor.

For a copy of the Safety Data Sheet (SDS) or to report adverse reactions call Bayer Veterinary Services at 1-800-422-9874. For consumer questions call 1-800-255-6826.

**Advantage Multi** is protected by one or more of the following U.S. patents: 6,232,328 and 6,001,858. NADA 141-251; 141-254 Approved by FDA

© 2015 Bayer

Bayer, the Bayer Cross, Advantage Multi are registered trademarks of Bayer.

Made in Germany.

V-03/2016